| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
|
| [2] |
Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242):2008-2020.
|
| [3] |
Bear AS, Vonderheide RH, O'Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy[J]. Cancer Cell, 2020, 38(6):788-802.
|
| [4] |
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer[J]. Nat Rev Clin Oncol, 2020, 17(2):108-123.
|
| [5] |
Mahalingam D, Wilkinson GA, Eng KH, et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ⅰb study[J]. Clin Cancer Res, 2020, 26(1):71-81.
|
| [6] |
Reiss KA, Mick R, O'Hara MH, et al. Phase Ⅱ study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2[J]. J Clin Oncol, 2021, 39(22):2497-2505.
|
| [7] |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
|
| [8] |
Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline[J]. J Clin Oncol, 2016, 34(22):2654-2668.
|
| [9] |
Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):285-294.
|
| [10] |
Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort[J]. Ann Surg Oncol, 2015, 22(1):295-301.
|
| [11] |
Seufferlein T, Hammel P, Delpero JR, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence[J]. Cancer Treat Rev, 2019(77):1-10.
|
| [12] |
Bednar F, Zenati MS, Steve J, et al. Analysis of predictors of resection and survival in locally advanced stage Ⅲ pancreatic cancer: does the nature of chemotherapy regimen influence outcomes?[J]. Ann Surg Oncol, 2017, 24(5):1406-1413.
|
| [13] |
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection[J]. Ann Surg, 2019, 270(2):340-347.
|
| [14] |
Stein SM, James ES, Deng Y, et al. Final analysis of a phase Ⅱ study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer[J]. Br J Cancer, 2016, 114(7):737-743.
|
| [15] |
Fiore M, Ramella S, Valeri S, et al. Phase Ⅱ study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer[J]. Sci Rep, 2017(7):45845.
|
| [16] |
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379(25):2395-2406.
|
| [17] |
Teriaca MA, Loi M, Suker M, et al. A phase Ⅱ study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome[J]. Radiother Oncol, 2021(155):232-236.
|
| [18] |
Buss EJ, Kachnic LA, Horowitz DP. Radiotherapy for locally advanced pancreatic ductal adenocarcinoma[J]. Semin Oncol, 2021, 48(1):106-110.
|
| [19] |
Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(7):1020-1027.
|
| [20] |
Hammel P, Huguet F, Van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853.
|
| [21] |
Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update[J]. J Clin Oncol, 2020, 38(27):3217-3230.
|
| [22] |
Macchini M, Centonze F, Peretti U, et al. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants[J]. Cancer Treat Rev, 2021(100):102262.
|
| [23] |
Sinn M, Sinn BV, Treue D, et al. TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial[J]. Clin Cancer Res, 2020, 26(14):3732-3739.
|